Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Intrexon Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) 

 

Intrexon Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI)
April 1, 2015 – (Intrexon) – Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Intrexon has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System platform for the treatment of solid tumor malignancies.  

 

 

Posted on 1-Apr-15 by Berry, Cassie
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: